{
  "patient_id": "PATIENT_001",
  "drug": "CLOPIDOGREL",
  "timestamp": "2026-02-19T13:30:00Z",
  "risk_assessment": {
    "risk_label": "Ineffective",
    "confidence_score": 0.95,
    "severity": "high"
  },
  "pharmacogenomic_profile": {
    "primary_gene": "CYP2C19",
    "diplotype": "*2/*2",
    "phenotype": "PM",
    "detected_variants": [
      {
        "rsid": "rs12248560",
        "ref": "G",
        "alt": "A",
        "genotype": "1/1"
      }
    ]
  },
  "clinical_recommendation": {
    "guideline": "Consider a clinically appropriate alternative antiplatelet not predominantly metabolized by CYP2C19 (e.g., prasugrel or ticagrelor)."
  },
  "llm_generated_explanation": {
    "summary": "Patient is a CYP2C19 Poor Metabolizer. Clopidogrel will be ineffective, increasing cardiovascular risk.",
    "biological_mechanism": "Because the patient has two copies of the non-functional *2 allele (rs12248560), their liver cannot convert the prodrug clopidogrel into its active form, leading to a high probability of therapeutic failure."
  },
  "quality_metrics": {
    "vcf_parsing_success": true,
    "variants_analyzed": 1
  }
}
